Last10K.com

Bristol Myers Squibb Co (BMY) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

BMY Annual Reports

10-K Annual Report February 2022
10-K Annual Report February 2021
10-K Annual Report February 2020
10-K Annual Report February 2019
10-K Annual Report February 2018
10-K Annual Report February 2017
10-K Annual Report February 2016
10-K Annual Report February 2015
10-K Annual Report February 2014

Bristol Myers Squibb Co

CIK: 14272 Ticker: BMY
Exhibit 99.1
bmslogo2021a.jpg

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
Reports Fourth Quarter Revenues of $12.0 Billion; Full-Year Revenues of $46.4 Billion
Posts Fourth Quarter Earnings Per Share of $1.07 and Non-GAAP EPS of $1.83; Posts Full- Year Earnings Per Share of $3.12 and Non-GAAP EPS of $7.51
Delivers Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios
Advances Pipeline with Achievement of Significant Clinical and Regulatory Milestones; Builds Strong Foundation for Portfolio Renewal
Announces $15 Billion Share Repurchase Authorization; $5 Billion Accelerated Share Repurchase Agreement to be Executed During the First Quarter 2022
Provides GAAP and More Detailed Non-GAAP Financial Guidance for 2022
Reaffirms Long-term Financial Targets

(NEW YORK, February 4, 2022) –
Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company’s pipeline that further progressed the company’s portfolio renewal.

“I am proud of how our company performed in 2021, helping more patients across our therapeutic areas, while achieving 9% revenue and 17% non-GAAP EPS growth, respectively,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb. “2021 was a pivotal year for our company as we achieved significant regulatory and clinical milestones and positioned the company to successfully renew our portfolio. I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed dose combination, mavacamten and deucravacitinib. Our financial strength, dedicated workforce and proven ability to execute will enable us to continue to advance our pipeline, invest in future sources of innovation and position the company for sustained growth.”

1


The following information was filed by Bristol Myers Squibb Co (BMY) on Friday, February 4, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Bristol Myers Squibb Co's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bristol Myers Squibb Co.

Continue

Assess how Bristol Myers Squibb Co's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bristol Myers Squibb Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Revenue
Legal
Financial
M & A
Other
Filter by Subcategory:
All
Product
Cash Flow
Expense
Shares
Debt
Earnings
Dividend
Geography
Income
Other
Inside Bristol Myers Squibb Co's 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Audit Information
Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income/(Loss)
Consolidated Statements Of Earnings
Accounting Policies And Recently Issued Accounting Standards
Accounting Policies And Recently Issued Accounting Standards (Details)
Accounting Policies And Recently Issued Accounting Standards (Policies)
Acquisitions, Divestitures, Licensing And Other Arrangements
Acquisitions, Divestitures, Licensing And Other Arrangements (Tables)
Acquisitions, Divestitures, Licensing And Other Arrangements - Additional Information (Details)
Acquisitions, Divestitures, Licensing And Other Arrangements - Business Acquisition, Pro Forma Information (Details)
Acquisitions, Divestitures, Licensing And Other Arrangements - Divestitures (Details)
Acquisitions, Divestitures, Licensing And Other Arrangements - Licensing And Other Arrangements (Details)
Acquisitions, Divestitures, Licensing And Other Arrangements - Schedule Of Consideration Transferred (Details)
Acquisitions, Divestitures, Licensing And Other Arrangements - Schedule Of Consideration Transferred - Asset Acquisition (Details)
Acquisitions, Divestitures, Licensing And Other Arrangements - Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed (Details)
Alliances
Alliances (Tables)
Alliances - Financial Information Pertaining To Alliances (2Seventy Bio) (Details)
Alliances - Financial Information Pertaining To Alliances (Eisai) (Details)
Alliances - Financial Information Pertaining To Alliances (Nektar) (Details)
Alliances - Financial Information Pertaining To Alliances (Ono) (Details)
Alliances - Financial Information Pertaining To Alliances (Otsuka) (Details)
Alliances - Financial Information Pertaining To Alliances (Pfizer) (Details)
Alliances - Financial Information Pertaining To Alliances (Total) (Details)
Earnings/(Loss) Per Share
Earnings/(Loss) Per Share (Details)
Earnings/(Loss) Per Share (Tables)
Employee Stock Benefit Plans
Employee Stock Benefit Plans (Tables)
Employee Stock Benefit Plans - Additional Information (Details)
Employee Stock Benefit Plans - Estimated Fair Value Of Options (Details)
Employee Stock Benefit Plans - Stock Based Compensation Expense (Details)
Employee Stock Benefit Plans - Summary Of Significant Outstanding And Exercisable Options (Details)
Employee Stock Benefit Plans - Summary Of Stock Compensation Activity (Details)
Equity
Equity (Tables)
Equity - Additional Information (Details)
Equity - Schedule Of Accumulated Other Comprehensive Income (Loss) (Details)
Equity - Schedule Of Comprehensive Income (Loss) (Details)
Equity - Schedule Of Stockholders Equity (Details)
Financial Instruments And Fair Value Measurements
Financial Instruments And Fair Value Measurements (Tables)
Financial Instruments And Fair Value Measurements - Additional Information (Details)
Financial Instruments And Fair Value Measurements - Available-For-Sale Securities (Details)
Financial Instruments And Fair Value Measurements - Derivative Instruments, Gain (Loss) (Details)
Financial Instruments And Fair Value Measurements - Gain/(Loss) On Hedging Activity (Details)
Financial Instruments And Fair Value Measurements - Schedule Of Derivatives And Fair Value (Details)
Financial Instruments And Fair Value Measurements - Schedule Of Equity Investments (Details)
Financial Instruments And Fair Value Measurements - Schedule Of Financial Assets And Liabilities Measured At Fair Value (Details)
Financial Instruments And Fair Value Measurements - Schedule Of Long-Term And Current Debt Instruments (Details)
Financial Instruments And Fair Value Measurements - Schedule Of Short-Term Debt (Details)
Financial Instruments And Fair Value Measurements - Summary Of Equity Investments Carrying Amount (Details)
Goodwill And Other Intangible Assets
Goodwill And Other Intangible Assets (Tables)
Goodwill And Other Intangible Assets - Additional Information (Details)
Goodwill And Other Intangible Assets - Schedule Of Intangible Assets By Major Class (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Details)
Income Taxes - Schedule Of Deferred Tax Assets And Liabilities (Details)
Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation (Details)
Income Taxes - Schedule Of Provision For Income Taxes (Details)
Income Taxes - Summary Of Income Tax Contingencies (Details)
Income Taxes - Summary Of Income Tax Examinations (Details)
Income Taxes - Summary Of Valuation Allowance (Details)
Inventories
Inventories (Details)
Inventories (Tables)
Leases
Leases (Tables)
Leases - Additional Information (Details)
Leases - Balance Sheet Information Related To Leases (Details)
Leases - Summary Of Components Of Lease Expense (Details)
Leases - Summary Of Operating Lease Maturity (Details)
Legal Proceedings And Contingencies
Legal Proceedings And Contingencies (Details)
Other (Income)/Expense, Net
Other (Income)/Expense, Net (Tables)
Other (Income)/Expense, Net - Schedule Of Other Income Expense (Details)
Property, Plant And Equipment
Property, Plant And Equipment (Details)
Property, Plant And Equipment (Tables)
Receivables
Receivables (Tables)
Receivables - Additional Information (Details)
Receivables - Receivables Allowance (Details)
Receivables - Schedule Of Accounts, Notes, Loans And Financing Receivable (Details)
Restructuring
Restructuring (Tables)
Restructuring - Additional Information (Details)
Restructuring - Schedule Of Restructuring And Related Costs (Details)
Restructuring - Schedule Of Restructuring Reserve By Type Of Cost (Details)
Retirement Benefits
Retirement Benefits (Tables)
Retirement Benefits - Actuarial Assumptions (Details)
Retirement Benefits - Additional Information (Details)
Retirement Benefits - Fair Value Of Pension And Postretirement Plan Assets By Asset Category (Details)
Retirement Benefits - Schedule Of Accumulated And Projected Benefit Obligation In Excess Of Fair Value Of Plan Assets (Details)
Retirement Benefits - Schedule Of Defined Benefit Obligations And Assets (Details)
Retirement Benefits - Schedule Of Net Benefit Costs (Details)
Revenue - Additional Information (Details)
Revenue - Disaggregation Of Revenue (Details)
Revenue - Disaggregation Of Revenue By Product And Region (Details)
Revenue - Reconciliation Of Gross Product Sales To Net Product Sales (Details)
Revenue - Schedule Of Revenue By Major Customers (Details)
Revenue Revenue
Revenue Revenue (Tables)
Supplemental Financial Information
Supplemental Financial Information (Tables)
Supplemental Financial Information - Other Current Assets (Details)
Supplemental Financial Information - Other Current Liabilities (Details)
Supplemental Financial Information - Other Non-Current Assets (Details)
Supplemental Financial Information - Other Non-Current Liabilities (Details)
Ticker: BMY
CIK: 14272
Form Type: 10-K Annual Report
Accession Number: 0000014272-22-000051
Submitted to the SEC: Wed Feb 09 2022 11:44:38 AM EST
Accepted by the SEC: Wed Feb 09 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/bmy/0000014272-22-000051.htm